To report a case of coexisting psoriasis and lichen planus and evaluate the efficacy of upadacitinib in treatment, highlighting its significance in the context of limited existing literature.
Key Findings:
Initial treatments with acitretin and topical mometasone were discontinued due to safety concerns, leading to a relapse.
Upadacitinib treatment resulted in marked improvement within 3 months, specifically in lesion size and patient-reported symptoms.
Interpretation:
The case suggests that upadacitinib may be an effective treatment option for patients with coexisting psoriasis and lichen planus, potentially due to its mechanism of action on immune pathways, particularly its inhibition of JAK-1 signaling.
Limitations:
This is a single case study, limiting generalizability and introducing potential biases.
Long-term efficacy and safety of upadacitinib in this context remain to be established.
Conclusion:
Upadacitinib shows promise in managing complex cases of psoriasis and lichen planus, warranting further investigation, particularly in larger, controlled studies.
